The International HapMap Consortium published analyses of its second-generation map of human genetic variation, which contains three times more markers than the initial version unveiled in 2005.
Researchers at the University of Warwick and Astra Zeneca have found a new way to use solid-state NMR equipment to crack the secrets of hydrogen atoms and thus spot unwanted polymorphs in pharmaceuticals.
Researchers have discovered the first microRNAs—tiny bits of code that regulate gene activity—linked to each of 10 major degenerative muscular disorders, opening doors to new treatments and a better biological understanding of these debilitating, poorly understood, often untreatable diseases.
Researchers at the Stanford University School of Medicine have developed a blood test that could give people a diagnosis two to six years in advance of the onset of Alzheimer's disease.
Researchers at the LSU School of Veterinary Medicine have engineered a herpes virus to potentially fight breast cancer.
New research identifies naturally occurring processes that allow many genes to both slow aging and protect against cancer in the much-studied C. elegans roundworm.
The epilepsy drug lamotrigine is effective in controlling partial seizures when taken once a day as an added therapy.
The Critical Path Institute (C-Path), Tuscon, Ariz., will use a $2.1 million grant from Science Foundation Arizona (SFAz) to develop performance standards and an evaluation process for companion diagnostics and their associated targeted cancer therapies.
Biophysicists at the University of Pennsylvania have discovered that the nuclei of human stem cells are particularly soft and flexible, rather than hard, making it easier for stem cells to migrate through the body.
MIT researchers have discovered a link between a gene believed to promote long lifespan and a pathway that flushes cholesterol from the body.
Increased levels of a protein called CUGBP1 play an important role in the adult-onset form of muscular dystrophy called myotonic dystrophy type 1.
Leading makers of over-the-counter cough and cold medicines announced October 11, 2007 voluntary market withdrawals of oral cough and cold medicines that refer to "infants."
Alacrity Biosciences, Laguna Hills, Calif., announced that its dry eye treatment, ALTY-0501, demonstrated statistically significant advantages over vehicle in its ability to control signs and symptoms of dry eye in a Phase 2 study.
Altheus Therapeutics, Inc., Oklahoma City, Okla., has secured $3.6 million in venture capital financing to fund clinical trials testing the efficacy of its therapy for the treatment of inflammatory bowel disease.